The New York Times, Sunday, March 4, 2001. Money Section:
Article mainly about Hemopure, but:
After mentioning ALLP January problems...
"But in a sign of how close many in the field believe they are to success, Alliance said it expects to resume the domestic (USA)trial this year. IN ADDITION, Alliance may apply in Europe for approval in general surgery, relying strictly on completed trials there, SAID Gwen Rosemberg, a spokeswoman."
"We could still end up as the first one out there, she said".
This is a lot of information released kind of candidly by the ALLP spokeswoman to the NY Times. I think it should be considered very seriously, especially after the ALLP official release about defending themselves vigorously against the Molecular lawsuit by shareholders.
It is very serious indeed, cause if not factual and the stock moves because of this it is ground for more lawsuits trouble.
I do hope is true and official, even if the chosen channel is kind of lax.
Caveat: I own shares of ALLP. I traded it twice in the past, and a swift move I will trade it again.
I do like the science, and the prospects. |
